-+ 0.00%
-+ 0.00%
-+ 0.00%

Propanc Biopharma plans Phase 1b trial of PRP proenzyme therapy in advanced solid tumors in Q4

PUBT·08/12/2026 12:35:15
Listen to the news
Propanc Biopharma plans Phase 1b trial of PRP proenzyme therapy in advanced solid tumors in Q4
  • Propanc Biopharma outlined plans to enter a first-in-human Phase 1b study of PRP in advanced solid-tumor patients, with emphasis on pancreatic cancer.
  • Results have not been presented; the company expects to file the clinical trial application in Q4 2026.
  • PRP is positioned as a non-cytotoxic, long-term therapy intended to slow disease spread and reduce relapse risk by reprogramming malignant cells.
  • The update highlighted supportive preclinical and compassionate-use observations, framing PRP as a potential backbone or maintenance option alongside existing treatments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120830PRIMZONEFULLFEED9808574) on August 12, 2026, and is solely responsible for the information contained therein.